1 Does Fecal Occult Blood Testing Really Reduce Mortality? A Reanalysis of Systematic Review Data Am J Gastroenterol 2006;101:380–384.

Slides:



Advertisements
Similar presentations
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Advertisements

Organized colorectal cancer screening program with FOBT: participation and diagnostic yield deteriorate with time Results – yield Aim To assess the short.
Presented by Dr Heather Murray GPEP1 Registrar on behalf of
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Use of Placebos in Controlled Trials. Background The traditional ‘double-blind’ RCT uses a placebo to conceal allocation. There are a number of advantages.
Spotlight on Colorectal Cancer Screening 1 1. Home Screening for Colon Cancer
Is There An Association? Exposure (Risk Factor) Outcome.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Colorectal Cancer Screening & Surveillance: Anything New? Timothy C. Hoops, M.D.
Prostate Cancer Screening: Con
CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.
Colorectal cancer: How do we approach health disparities? Marta L. Davila, MD, FASGE University of Texas MD Anderson Cancer Center.
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Early Detection of breast cancer Anthony B. Miller, MD, FRCP Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Canada.
Haley Hyde Jessica Fordham Jena Hamm  Colorectal cancer is a leading cause of cancer related deaths every year.  150,000 Americans will be diagnosed.
Tryggvi Björn Stefánsson Dept of Surgery Landspitali University Hospital.
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
Making all research results publically available: the cry of systematic reviewers.
Ethical issues and cancer screening. Efficacy The extent to which a specific intervention, procedure, regimen, or service produces a beneficial result.
Azara Proprietary & Confidential Overview June 2014 Improving Patient Outcomes through Data.
Stage-specific survival of screen-detected versus clinically diagnosed colorectal cancer - evidence from the FOBT screening trials- Iris Lansdorp-Vogelaar.
AIMGP Seminar Series January 2004 Joo-Meng Soh Edited by Gloria Rambaldini CANCER SCREENING PART II.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Our Vision – Healthy Kansans Living in Safe and Sustainable Environments.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Design of Phase III Microbicide Trials: Choice of Control Group August 20, 2003 Rosalie Dominik, DrPH Director of Biostatistics Institute for Family Health.
Colorectal Cancer (CRC) Surveillance: Introduction and Overview Carrie Klabunde, Ph.D. IBSN Biennial Meeting Ottawa, Canada May 11-12, 2006.
An Evidence Based Approach to Colorectal Cancer Screening J. C. Ryan, M.D. Associate Professor of Medicine UCSF and SF VAMC 9/22/2014.
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
Models to Inform Recommendations About Preventive Services Perspective of the United States Preventive Services Task Force.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Brian Cox Research Associate Professor: Cancer epidemiology and screening University of Otago Hugh Adam Cancer Epidemiology Unit Department of Preventive.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Colorectal Cancer Proposal of a Screening Program for Developing Countries with Emphasis on Costs.
Issues concerning the interpretation of statistical significance tests.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Colorectal Cancer Screening Colorectal Cancer Screening VT SGNA Conference VT SGNA Conference October 24, 2015 October 24, 2015 Lynn Butterly, MD Lynn.
PaRROT Program Introduction. Learning objectives Understand and be aware of: History, objectives principles and expected outcomes of PaRROT Program content,
Factors Predicting Stage of Adoption for Fecal Occult Blood Testing and Colonoscopy among Non-Adherent African Americans Hsiao-Lan Wang, PhD, RN, CMSRN,
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Making Decisions. The act of making a choice or coming to a solution that can affect: – Your health and well-being – Someone else’s health or well-being.
 Allows researchers to detect cause and effect relationships  Researchers manipulate a variable and observe whether any changes occur in a second variable.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
The evidence for going to scale with Calcium supplementation Harshad Sanghvi Vice-President & Medical Director, Jhpiego Senior Advisor, Accelovate/USAID,
1 Evidence based health SCREENING Dr.Hathaitip Tumviriyakul Diploma Family medicine,Hatyai Hospital Msc. Epidemiology LSHTM,UK.
Cancer prevention and early detection
Clinical Epidemiology
Introduction: “Please write down everything that comes into your head when you hear the words ‘DNA risk tests’” Colorectal cancer Type 1 diabetes Information.
Colorectal Cancer Screening Guidelines
What you need to know about the Fecal Occult Blood Test
The Burden of Colorectal Cancer in Arkansas
Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Confidence Intervals and p-values
More Ontarians need to be screened for colorectal cancer (Sept. 2012)
Systematic Review Systematic review
Bowel cancer screening update GP education event 28 Nov 2017
Evidence of a Program's Effectiveness in Improving Colorectal Cancer Screening Rates in Federally Qualified Health Centers Robert L. Stephens, PhD, MPH1;
Colorectal Cancer Screening
Evaluation of a Spiritually-based Intervention to Increase Colorectal Cancer Knowledge and Screening Among Church-attending African Americans and Whites.
مقدمه‌ای بر طب مبتنی بر شواهد
Comprehensive Meta-Analysis of DES vs
Citation: Cancer Care Ontario
The Research Question Flexible sigmoidoscopy (FS) is the only cancer screening modality (for any type of cancer) to reduce all-cause mortality compared.
Challenges in Evaluating Screening & Prevention Interventions
Smoothed colorectal cancer mortality rate (per 100 000 person-years) in the screening and control arm over follow-up time, and ratio of the mortality rates.
Genomic Medicine in Community Health: Protecting Human Rights
Presentation transcript:

1 Does Fecal Occult Blood Testing Really Reduce Mortality? A Reanalysis of Systematic Review Data Am J Gastroenterol 2006;101:380–384

2 CRC Screening The choices available for CRC screening are:  FOBT  flexible sigmoidoscopy every 5 yr  colonoscopy every 10 yr  CT colography The choices available for CRC screening are:  FOBT  flexible sigmoidoscopy every 5 yr  colonoscopy every 10 yr  CT colography

3 CRC Screening FOBT has the most RCT evidence to support a reduction in CRC mortality FOBT is also less expensive than the other alternatives and is the only strategy that many health-care systems can afford. Is the endpoint of CRC death an ideal endpoint? Maybe “all cause” mortality should be the most appropriate outcome to evaluate. FOBT has the most RCT evidence to support a reduction in CRC mortality FOBT is also less expensive than the other alternatives and is the only strategy that many health-care systems can afford. Is the endpoint of CRC death an ideal endpoint? Maybe “all cause” mortality should be the most appropriate outcome to evaluate.

4 CRC Screening The value of FOBT in preventing CRC mortality is accepted. This study evaluates whether FOBT reduces all cause mortality as an outcome. The value of FOBT in preventing CRC mortality is accepted. This study evaluates whether FOBT reduces all cause mortality as an outcome.

5 CRC Screening שימוש ב -FOBT ל -screening מביא ירידה של 16% בתמותה מ -CRC.

6 במטה - אנליזה נכללו שלושה מחקרים רקע Mandel et al. N Engl J Med 1993;328;1365–71. Scholefield et al. Gut 2002;50:840–4. Jorgensen et al. Gut 2002;50:29–32.

7 CRC mortality in FOBT arm compared with no screening arm תוצאות שימוש ב -FOBT ל -screening מביא ירידה של 13% בתמותה מ -CRC.

8 mortality not due to colorectal cancer in FOBT arm compared with no screening arm. תוצאות שימוש ב -FOBT ל -screening מעלה את שיעור התמותה מסיבות שאינן קשורות ל - !!CRC

9 all cause mortality in FOBT arm compared with no screening arm. תוצאות שימוש ב -FOBT ל -screening לא משפיע על שיעור התמותה מסיבה כלשהי.

10 דיון Concern with using all cause mortality as an outcome is that the power to detect clinically meaningful differences is diminished. The analysis of the data suggests that FOBT has no impact in overall mortality as there is an excess of deaths from non-CRC causes. Concern with using all cause mortality as an outcome is that the power to detect clinically meaningful differences is diminished. The analysis of the data suggests that FOBT has no impact in overall mortality as there is an excess of deaths from non-CRC causes. This seems counterintuitive as FOBT is an innocuous test and it is hard to conceive that this would result in death. Assuming that this is not a chance finding, there are three explanations for this unexpected result. This seems counterintuitive as FOBT is an innocuous test and it is hard to conceive that this would result in death. Assuming that this is not a chance finding, there are three explanations for this unexpected result.

11 הסבר I If a screening program reduces CRC deaths and subjects are followed up for long enough they will die from something else and there will be an apparent excess mortality from other causes. The problem with this explanation is that the follow- up in these trials has been for less than 13 yr in most cases with only 26% of subjects dying so far. If a screening program reduces CRC deaths and subjects are followed up for long enough they will die from something else and there will be an apparent excess mortality from other causes. The problem with this explanation is that the follow- up in these trials has been for less than 13 yr in most cases with only 26% of subjects dying so far.

12 הסבר II These trials were all open label. The behavior of both the subjects and the clinicians looking after them may be affected by the knowledge that FOBT has taken place. This bias would be particularly important when assessing the cause of death. These trials were all open label. The behavior of both the subjects and the clinicians looking after them may be affected by the knowledge that FOBT has taken place. This bias would be particularly important when assessing the cause of death.

13 הסבר III FOBT screening results in a real increase in deaths from other causes. It is not conceivable that this is due to the test directly but there are biologically plausible reasons why the psychological effects of screening may increase mortality. Subjects taking part in screening may feel that this protects them from harm and conduct a lifestyle that increases their risk of mortality. FOBT screening results in a real increase in deaths from other causes. It is not conceivable that this is due to the test directly but there are biologically plausible reasons why the psychological effects of screening may increase mortality. Subjects taking part in screening may feel that this protects them from harm and conduct a lifestyle that increases their risk of mortality.

14 קיים הסבר נוסף שאינו מופיע במאמר

15 הסבר IV ההסבר האולטימטיבי יש טעות בחישובים של המאמר. אין הבדל בשיעור התמותה מסיבה שלא קשורה ל - CRC. לפי המאמר ה - RR בעבודה של Schoiefield הוא 1.03, אך בפועל ה - RR הוא !! לפי המאמר ה - Pooled RR לתמותה שלא קשורה ל - CRC הוא 1.02, אך בחישוב שעשינו קבלנו RR=1.007 עם CI=(0.993,1.021)! אין תקפות למאמר !!!! יש טעות בחישובים של המאמר. אין הבדל בשיעור התמותה מסיבה שלא קשורה ל - CRC. לפי המאמר ה - RR בעבודה של Schoiefield הוא 1.03, אך בפועל ה - RR הוא !! לפי המאמר ה - Pooled RR לתמותה שלא קשורה ל - CRC הוא 1.02, אך בחישוב שעשינו קבלנו RR=1.007 עם CI=(0.993,1.021)! אין תקפות למאמר !!!!